Promedior Stock

promedior.comHealthcare / BioTech & PharmaFounded: 2006Funding to Date: $76MM

Developer of therapeutics designed to treat fibrotic diseases. The company develops a drug discovery platform to regulate the monocyte-derived cell populations that play roles in fibrotic, inflammatory and autoimmune diseases, enabling patients with medicines to cure their diseases.

Register To Buy and Sell Shares

For more details on financing and valuation for Promedior, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Promedior’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Promedior.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Richard Jack Ph.D
President, Chief Scientific Officer & Chief Operating Officer
Renu Gupta
Chief Medical Officer
W. Scott Willett Ph.D
Vice President of Biopharmaceutical Development
Nancy Thomason
Chairman
Jason Lettmann
Chief Executive Officer & Board Member
Kieran McCarthy
Vice President of Business Development

Board Members

Geert-Jan Mulder MD
Forbion
Jason Lettmann
Paul Goldenheim MD
Howard Weisman
Nancy Thomason
Augustine Lawlor
John Friedman JD
Easton Capital Investment Group
Updated on: Dec 10, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.